Acromegaly Clinical Trial
Official title:
FACIAL AND HAND ANALYSIS, SLEEP APNEA AND SPEECH IN PATIENTS WITH ACROMEGALY: A PROSPECTIVE STUDY TO INVESTIGATE CHANGES IN CRANIOFACIAL AND HAND CHARACTERISTICS, SLEEP APNEA AND SPEECH DURING TREATMENT AND AFTER REMISSION
Rationale: Acromegaly is the clinical syndrome that results from an excess of growth hormone
(GH). Craniofacial and hand disproportions due to soft tissue swelling and new bone
formation are highly prevalent in patients with active acromegaly. Besides the cosmetic
aspects, these changes can impair the quality of life because of the significant morbidity
with respect to oral, maxillofacial and hand pathologies as well as respiratory problems
such as sleep apnea and changes in speech. At present it is unclear if these craniofacial
and hand disproportions, sleep apnea and speech changes are (partially) reversible after
successful treatment. Therefore there is no consensus about the information patients should
be given about (partial) recovery of facial and hand disproportions after treatment and how
the follow-up with respect to oral, maxillofacial, respiratory and hand pathology should be
organized. Facial and hand analysis using a 3D stereophotograph and a 3D fusion model of a
3D stereophotograph and a 3D skull reconstruction via cone beam computed tomography
(CT)-scan makes it possible to investigate the craniofacial changes due to acromegaly in all
facial dimensions together (dentition, bone and soft tissue) and the relational proportions
between these facial structures. 3D stereophotography can do the same for the soft tissues
of the hand. Combined with disease specific and general quality of life (QOL)
questionnaires, a correlation between quality of life and craniofacial and hand
disproportions can be determined. Combined with sleep- and speech analysis, a correlation
between sleep apnea, speech and craniofacial disproportions can be determined.
Primary objective: To investigate the changes in facial- and hand analysis in patients with
acromegaly as a result of medical treatment and pituitary surgery, and to investigate the
changes in relational proportions between facial- and hand structures, incidence and
severity of sleep apnea, incidence and severity of speech changes and QOL.
Study design: a prospective case-control study. Study population: Approximately thirty
patients newly diagnosed with acromegaly . The results of facial and hand analysis, sleep
apnea research and speech analysis of the patient group in different phases of the disease
will be compared to the results of a healthy control group.
Main study parameters/endpoints: Parameters of facial analysis with 3D stereophotography and
cone beam CT and hand analysis with 3D stereophotography , biochemical parameters of disease
activity, disease related QOL assessed by 2 validated QOL questionnaires (,the AcroQol and
RAND-36 ), speech analysis, the results of the voice handicap index questionnaire and
severity of sleep apnea assessed by complete overnight polysomnography and the Epworth
sleepiness scale questionnaire.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: As a result of participating in this study, subjects have to undergo a cone
beam CT. The cone beam CT is associated with exposure to X-ray radiation of 0.069-0.135mSv.
This is the same amount of radiation as the amount of background radiation that each person
receives in 7 days time during daily life. No adverse effects are expected from this amount
of exposure. The investigations will take 10-70 minutes adjacent to every regular outpatient
clinic visit. In addition , for polysomnography, subjects will be investigated overnight one
or three times in 2,5 years, depending on the results of the first screening
polysomnography.
Assessment of changes in body appearance, sleep disturbances, speech changes and QOL in a
prospective longitudinal fashion will increase the knowledge of the impact of the disease on
patient perception of well-being and functioning and will help us refine the treatment goals
in patients with acromegaly
n/a
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
Completed |
NCT02012127 -
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
|
||
Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 |